

## **e-Therapeutics plc**

("e-Therapeutics" or the "Company")

### **Completion of the Placings**

e-Therapeutics, the drug discovery and development company, is pleased to announce completion of the Second Placing, following the admission of a further 65,384,615 new ordinary shares in the Company to trading on AIM.

Following the announcement made on 3 March 2011, confirming the passing of the resolutions put to the General Meeting held that day, and the AIM notice on 4 March 2011 confirming the admission of 5,655,400 new ordinary shares arising from completion of the First Placing and the Warrant Exercise, the Placings are now completed.

The conditions relating to the sale and purchase of secondary shares referred to in the announcement of the Placings on 15 February 2011, and described in the Circular to Shareholders of the same date, are also now unconditional.

Following completion of the Placings, the total number of ordinary shares in issue in the Company is now 137,193,547.

The above figure (137,193,547 ordinary shares) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the FSA's Disclosure and Transparency Rules.

7 March 2011.

#### **For more information, please contact:**

##### **e-Therapeutics plc**

Malcolm Young / John Cordiner

Tel: +44 (0) 191 233 1317

E-mail: [malcolm@etherapeutics.co.uk](mailto:malcolm@etherapeutics.co.uk)

[www.etherapeutics.co.uk](http://www.etherapeutics.co.uk)

**Panmure Gordon (UK) Limited**

Andrew Burnett / Aubrey Powell

Tel: +44 (0) 20 7459 3600

[www.panmure.com](http://www.panmure.com)